Leigh's disease

(redirected from Leigh syndrome)
Also found in: Acronyms.

Leigh's disease

Subacute necrotizing encephalopathy A mitochondrial disease of infants Clinical Progressive loss of motor and verbal skills Prognosis Usually fatal by age 2. See Mitochondrial disease.
References in periodicals archive ?
Clinical, biochemical, and molecular analysis of a maternally inherited case of Leigh syndrome (MILS) associated with the mtDNA T8993G point mutation.
The patient was admitted to the Pediatric Neurology Department for further examination based on the suspicion of Moyamoya disease associated with Leigh syndrome.
Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome.
She and Spiros, who live in Worcester, did not understand how serious Leigh Syndrome was when they were first given the diagnosis.
MRT has enabled the parents to have a healthy child after the loss of two children to Leigh syndrome.
6-11) For example, a DNA sample was recently received from a one-year-old female with clinical symptoms suggestive of Leigh syndrome, a mitochondria-associated disorder, which includes difficulty swallowing, motor delay, and involuntary eye movement.
Eventually, after 10 months, she was diagnosed with Leigh Syndrome, a neurological condition which causes scarring on the brain tissue.
Raptor's R&D pipeline includes RP103, known commercially as PROCYSBI, for Huntington's disease and mitochondrial disorders, including Leigh syndrome.
Recently the company announced that it was undertaking phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich's ataxia.
LEIGH'S disease, a form of Leigh syndrome, also known as Subacute Necrotizing Encephalomyelopathy (SNEM), is a rare disorder that affects the central nervous system.
Edison looks to develop the Phase IB drug candidate EPI-589 for adult central nervous system disease as well as EPI-743, an FDA-designated orphan drug in Phase II clinical development for inherited respiratory chain disorders, with ongoing placebo trials for Leigh syndrome, cobalamin C defect, undiagnosed disorders of oxidation-reduction, and Friedreich's ataxia.